Barclays Lowers HCA Healthcare (NYSE:HCA) Price Target to $366.00

HCA Healthcare (NYSE:HCA) had its price objective dropped by research analysts at Barclays from $392.00 to $366.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price target would suggest a potential upside of 11.45% from the stock’s current price.

Other analysts have also recently issued research reports about the stock. KeyCorp lowered their price objective on shares of HCA Healthcare from $420.00 to $370.00 and set an “overweight” rating for the company in a research report on Tuesday, January 7th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $380.00 price objective on shares of HCA Healthcare in a report on Tuesday, December 17th. Truist Financial cut their price target on shares of HCA Healthcare from $430.00 to $390.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Oppenheimer raised their price objective on shares of HCA Healthcare from $390.00 to $400.00 and gave the stock an “outperform” rating in a report on Monday, October 28th. Finally, Morgan Stanley dropped their price target on HCA Healthcare from $406.00 to $355.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 17th. One research analyst has rated the stock with a sell rating, three have given a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $382.19.

HCA Healthcare Trading Down 1.1 %

Shares of NYSE HCA opened at $328.39 on Monday. The company’s 50 day simple moving average is $313.42 and its 200 day simple moving average is $353.24. The company has a debt-to-equity ratio of 48.71, a current ratio of 1.12 and a quick ratio of 1.00. The firm has a market capitalization of $83.18 billion, a P/E ratio of 14.75, a P/E/G ratio of 1.09 and a beta of 1.64. HCA Healthcare has a fifty-two week low of $281.61 and a fifty-two week high of $417.14.

HCA Healthcare (NYSE:HCA) last issued its earnings results on Friday, January 24th. The company reported $6.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.03 by $0.19. HCA Healthcare had a return on equity of 520.98% and a net margin of 8.52%. During the same quarter in the previous year, the company earned $5.90 EPS. On average, analysts predict that HCA Healthcare will post 21.75 EPS for the current year.

Insiders Place Their Bets

In related news, insider Erol R. Akdamar sold 2,900 shares of the stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $353.00, for a total transaction of $1,023,700.00. Following the sale, the insider now owns 6,843 shares of the company’s stock, valued at $2,415,579. This represents a 29.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Phillip G. Billington sold 3,897 shares of the company’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $350.00, for a total value of $1,363,950.00. Following the sale, the senior vice president now owns 52,702 shares of the company’s stock, valued at approximately $18,445,700. The trade was a 6.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. FMR LLC lifted its position in shares of HCA Healthcare by 322.3% during the 3rd quarter. FMR LLC now owns 3,141,769 shares of the company’s stock worth $1,276,909,000 after buying an additional 2,397,883 shares during the last quarter. Franklin Resources Inc. boosted its stake in shares of HCA Healthcare by 11.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,669,721 shares of the company’s stock valued at $660,842,000 after purchasing an additional 174,946 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in HCA Healthcare by 2.8% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,487,367 shares of the company’s stock worth $604,511,000 after purchasing an additional 41,190 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of HCA Healthcare by 12.0% during the third quarter. Janus Henderson Group PLC now owns 1,339,638 shares of the company’s stock worth $544,467,000 after buying an additional 143,995 shares during the last quarter. Finally, Nordea Investment Management AB lifted its stake in shares of HCA Healthcare by 29.7% in the 4th quarter. Nordea Investment Management AB now owns 843,764 shares of the company’s stock valued at $253,020,000 after acquiring an additional 193,075 shares during the last quarter. 62.73% of the stock is currently owned by institutional investors and hedge funds.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.